ArticleClinical rheumatology2025
Knowledge mapping of plasmacytoid dendritic cells in systemic lupus erythematosus: a bibliometric analysis (2004-2023).
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasmacytoid dendritic cells (pDCs) are a specialized subset of dendritic cells known for their ability to produce type I interferon (IFN I), contributing to antiviral defense and the pathogenesis of autoimmune diseases like systemic lupus erythematosus (SLE). In SLE patients, pDCs are excessively activated, leading to overproduction of IFN-α, which plays a critical role in disease progression. However, no bibliometric analysis has been conducted on the relationship between pDCs and SLE. This study aims to map the knowledge structure and trends in research on pDCs in SLE through bibliometric analysis.
methodsWe analyzed publications related to pDCs in SLE from 2004 to 2023 using the Web of Science Core Collection. Data were analyzed and visualized with VOSviewers, CiteSpace, and the R package bibliometrix, offering a comprehensive view of the research landscape.
resultsThe analysis included 1086 articles from 57 countries, with the USA leading in publication volume. Major contributing institutions include Uppsala University, University of Michigan, and Baylor Institute for Immunology Research. Among the 565 authors, Ronnblom Lars was the most prolific, while Elkon Keith B ranked highest in terms of network centrality. Key research themes focus on pDC mechanisms in SLE development and emerging therapeutic strategies. Trending topics include "anifrolumab," "mortality," and "population."
conclusionThis bibliometric study provides a thorough overview of research trends on pDCs in SLE, identifying recent advances and key areas of interest, offering valuable insight for future research directions. KEY POINTS: • pDCs play a crucial role in systemic lupus erythematosus (SLE) through the overproduction of type I interferon (IFN-α). • This is the first bibliometric analysis mapping the research landscape of pDCs in SLE from 2004 to 2023. • Emerging research focuses on therapeutic strategies, including trending topics like "anifrolumab" and "mortality" in SLE. • This study offers valuable insights into key research themes and trends, guiding future investigations on pDCs in SLE.
Indexed as
Identifiers
40920265What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.